Impact of population admixture on the distribution of the CYP3A5·3 polymorphism

Pharmacogenomics

Volumn 8, Issue 10, 2007, Pages 1299-1306

  Suarez Kurtz, Guilherme ^a   Perini, Jamila A ^a   Bastos Rodrigues, Luciana ^b   Pena, Sergio D J ^b   Struchiner, Cláudio ^c  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Ancestry informative markers; Brazil; CYP3A5; Genetic polymorphism; Nonlinear logistic analysis; Pharmacogenetics; Population admixture; Population stratification

Indexed keywords

CYTOCHROME P450 3A5; DNA;

ADULT; ALLELE; ARTICLE; BIOGEOGRAPHY; BRAZIL; CAUCASIAN; CONTROLLED STUDY; DATA ANALYSIS; ETHNIC DIFFERENCE; FEMALE; FISHER EXACT TEST; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN CELL; LOGISTIC REGRESSION ANALYSIS; MALE; NEGRO; NONLINEAR REGRESSION ANALYSIS; NORMAL HUMAN; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; POPULATION GENETICS; POPULATION STRUCTURE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SELF REPORT;

BRAZIL; CONTINENTAL POPULATION GROUPS; CYTOCHROME P-450 CYP3A; ETHNIC GROUPS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; INTRONS; MALE; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; REGRESSION ANALYSIS;

EID: 36448951188     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.10.1299     Document Type: Article

References (39)

1. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G. Fusem S: CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet. Genomics 17 (2), 93-101 (2007).
2. Kuehl P. Zhang J, Lin Y et al.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27(4), 383-391 (2001). Original description of CYP3A5 Spolymorphisms.
3. Lambe JK, Lin YS, Schuet. EG, Thummel KE: Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. 54 a (10). 1271-1294 (2002).
4. Thompson EE, Kuttab-Boulos H, Witonsky D, Yang L, Roe BA, Di Rienzo A: CYP3A variation and the evolution of salt-sensitivity variants. Am. J. Hum. Genet. 75(6), 1059-1069 (2004).
5. Garsa AA, McLeod HL, Marsh S: CYP3A4 and CYP3A5 genotyping by pyrosequencing. BMC Med. Genet. 6,19 (2005).
6. Roy JN, Lajoie J, Zijenah LS et al.: CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab. Dispos. 33(7). 884-887 (2005).
7. Hustert E, Haberl M, Burk O et al.: The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetic 11 (9). 773-779 (2001).
8. Zeigler-Johnson C, Friebel T, Walker AH et al: CYP3A4, CYP3A5, and CYP3A43 genotypes haplotypes in the etiology and severity of prostate cancer. Cancer Res. 64(22). 1461-1467 (2004).
9. Floyd MD, Gervasini G, Masica AL et al.: Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 13(10), 595-606 (2003).
10. Parra EJ, Kitties RA, Shriver MD: Implications of correlations between skin color and genetic ancestry for biomedical research. Nat. Genet. 36(11), S54-S60 (2004).
11. Parra, EJ: Admixture in North America. In: Pharmacogenomics in Admixed Populations. Suarez-Kurtz G (Ed.). Landes Bioscience, TX, USA, 28-46 (2007).
12. Salzano FM, Bortolini MC: The Evolution and Genetics of Latin American Populations. Cambridge University Press, Cambridge. UK (2002).
13. Parra FC, Amado RC, Labertucci JR, Rocha J. Antunes CM, Pena SDJ: Color and genomic ancestry in Brazilians. Proc. Natl. Acad Sci. USA 100(1). 177-182 (2003).
14. Suarez-Kurtz G: Pharmacogenetics in admixed populations. Trends Pharmacol. Sci. 26(4). 196-201 (2005).
15. Suarez-Kurtz-G, Vianna-Jorge R. Perini J, Pena SDJ: Detection of CYP2C9*5 in a white Brazilian subject. Clin. Pharmacol. ther. 77(6), 587-588 (2005).
16. Suarez-Kurtz G, Pena SDJ: Pharmacogenomics in the Americas: impact of genetic admixture. Curr. Drug Targets 7(12). 1649-1658 (2006).
17. Suarez-Kurtz G, Pena SDJ: Pharmacogenetics in the Brazilian population. In: Pharmacogenomics in Admixed Populations. Suarez-Kurtz G (Ed.). Landes Bioscience, TX USA, 75-98 (2007).
18. Suarez-Kurtz G, Vargens DD, Struchiner CJ, Bastos-Rodrigues L, Pena SDJ: Self-reported skin color, genomic ancestry and the distribution of GST polymorphisms. Pharmacogenetic Genomics 17(9), 765-771 (2007).
19. Liu TC, Lin SF, Chen TP, Chang JG:- Polymorphism analysis of CYP3A5 in myeloid leukemia. Oncol Rep. 9(2), 327-329 (2002).
20. Bastos-Rodrigues L, Pimenta JR, Pena SDJ: The genetic structure of human populations studied through short insertion-deletion polymorphisms. Ann. Human Genet. 70(5), 658-665 (2006).
21. Pritchard JK, Stephens M, Donnelly P: Inference of population structure using multilocus genotype data. Genetics 155(2), 945-959 (2000).
22. Harrell FE: Regression Modeling Strategies: with Applications to linear Models. Logistic Regression, and Survival Analysis. Springer, NY, USA (2001).
23. R Development Core Team. R: A Language and Environment for Statistical Computing, Reference Index Version 2.2.1. R Foundation for Statistical Computing, Vienna, Austria (2005).
24. Hothorn T, Hornik K, van de Wiel MA, Zeileis Á: A Lego System for conditional inference. American Statistician 60, 257-263 (2006).
25. Fiegenbaum M, da Silveira FR, van der Sand CR et al.: The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin. Pharmacol. Ther. 78(5), 551-558 (2005).
26. Rossini A, Rapozo DC, Amorim LM et al.: Frequencies of GSTM1, GSTT1, and GSTP1 polymorphisms in a Brazilian population. Genet. Mol. Res. 1(3), 233-240 (2002).
27. Bóson WL, Romano-Silva MA, Correa H, Falcão RP, Teixeira-Vidigal PV, de Marco L: Thiopurine methyltransferase polymorphisms in a Brazilian population. Pharmacogenomics J. 3(3), 178-182 (2003).
28. Pereira AC, Morandini Filho AAF, Heimann AS et al.: Serum angiotensin converting enzyme activity association with the I/D polymorphism in an ethnically admixtured population. Clin. Chim. Acta 360(1-2), 201-204 (2005).
29. Zanrosso CW, Hatagima A, Emerenciano M et al.: The role of methylenetetrahydrofolate reductase in acute lymphoblastic leukemia in a Brazilian mixed population. Leuk. Res. 30(4), 477-481 (2006).
30. Cheung CY, Op den Buijsch RA, Wong KM et al.: Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients. 7(4), 563-574 (2006).
31. Roy JN, Barama A, Poirier C, Vinet B, Roger M: Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet. Genomics 16(9), 659-565 (2006).
32. Renders L. Frisman M. Ufer M et al.: CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. 81(2), 228-234 (2007).
33. Kamdem LK, Streit F, Zanger UM et al.: Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin. Chem. 51(8), 1374-1381 (2005).
34. Park JY, Kim KA, Park PW et al.: Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects. Clin. Pharmacol. Ther. 79(6), 590-599 (2006).
35. Josephson F, Allqvist A, Janabi M et al.: CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir. Clin. Pharmacol. Ther. 81(5), 708-712 (2007).
36. Balding DJ: A tutorial on statistical methods for population association studies. Nat. Rev. Genet. 7(10), 781-791 (2006).
37. Reiner AP, Carlson CS, Ziv E, Iribarren C, Jaquish CE, Nickerson DA: Genetic ancestry, population sub-structure, and cardiovascular disease-related traits among African-American participants in the CARDIA Study. Hum. Genet. 121(5), 565-575 (2007).
38. Barnholtz-Sloan JS, Chakraborty R, Sellers TA, Schwartz AG: Examining population stratification via individual ancestry estimates versus self-reported race. Cancer Epidemiol. Biomarkers Prev. 14(6), 1545-1551 (2005).
39. McLeod HL: Pharmacogenetics in the African-American Population: In: Pharmacogenomics in Admixed Populations. Suarez-Kurtz G (Ed.). Landes Bioscience, TX, USA, 47-59 (2007).